Table 1.
Primary screening hits
| Compound name | NCC compound number | HCV infection, % of control | Toxicity, biomass | EC50, μM | Error | EC90, μM | Error | LD50, μM | Error | LD50/EC50 | LD50/EC90 | Reported antiviral activity |
| Cyproheptadine | CPD000058431 | 0.3 | 72.2 | 0.7 | 0.2 | 3.0 | 0.0 | 33.5 | 1.5 | 51.5 | 11.2 | |
| Toremifene | CPD000469213 | 0.6 | 86.2 | 0.5 | 0.0 | 1.8 | 0.2 | 19.7 | 0.3 | 40.7 | 11.1 | |
| Fluphenazine | CPD000058411 | 0.0 | 76.5 | 0.5 | 0.2 | 1.4 | 0.6 | 14.5 | 5.5 | 29.0 | 10.4 | |
| Trifluoperazine | CPD000059133 | 0.3 | 86.9 | 0.6 | 0.3 | 1.7 | 0.5 | 16.5 | 1.5 | 30.0 | 10.0 | EBV entry (24) |
| Pizotyline | CPD000466272 | 0.0 | 69.8 | 0.7 | 0.1 | 3.0 | 0.0 | 28.0 | 2.0 | 39.1 | 9.3 | |
| Pterostilbene | CPD000440694 | 0.0 | 68.6 | 1.7 | 0.1 | 3.0 | 0.0 | 28.0 | 2.0 | 16.5 | 9.3 | |
| CGS 12066B | CPD000468733 | 0.3 | 106.9 | 1.0 | 0.0 | 3.5 | 0.5 | 32.5 | 2.5 | 32.5 | 9.3 | |
| Prochlorperazine | CPD000466275 | 0.0 | 72.8 | 1.3 | 0.7 | 3.3 | 0.8 | 29.3 | 12.3 | 22.3 | 9.0 | |
| Rabeprazole | CPD000469174 | 4.0 | 113.6 | 1.6 | 0.4 | 7.5 | 2.5 | 66.5 | 13.5 | 40.6 | 8.9 | |
| Doxepin | CPD000449270 | 14.7 | 99.2 | 4.0 | 2.0 | 9.5 | 5.5 | 65.0 | 15.0 | 16.3 | 6.8 | |
| Ketotifen | CPD000058462 | 11.1 | 105.9 | 4.9 | 3.1 | 12.3 | 0.3 | 72.3 | 27.8 | 14.8 | 5.9 | |
| MK886 | CPD000466278 | 5.4 | 110.3 | 2.1 | 0.1 | 6.5 | 0.5 | 37.5 | 12.5 | 17.9 | 5.8 | HCV infection (23) |
| Amiodarone | CPD000058296 | 1.3 | 95.7 | 0.9 | 0.3 | 4.4 | 0.6 | 21.8 | 6.8 | 23.3 | 4.9 | SARS-CV entry (25) |
| Imatinib | CPD000469175 | 0.1 | 76.8 | 2.8 | 0.2 | 5.5 | 0.5 | 25.5 | 4.5 | 9.2 | 4.6 | |
| Lacidipine | CPD000466342 | 0.0 | 72.4 | 1.8 | 0.3 | 4.3 | 0.3 | 17.5 | 7.5 | 10.0 | 4.1 | |
| SB 205607 | CPD000466296 | 13.3 | 109.3 | 4.5 | 1.5 | 12.5 | 2.5 | 49.5 | 0.5 | 11.1 | 4.0 | |
| Lofepramine | CPD000469292 | 7.8 | 104.3 | 2.3 | 1.3 | 9.5 | 5.5 | 37.5 | 2.5 | 16.7 | 3.9 | |
| Rimcazole | CPD000466293 | 0.0 | 81.0 | 1.5 | 0.0 | 5.0 | 0.0 | 19.7 | 10.7 | 13.0 | 3.9 | |
| Mifepristone | CPD000058481 | 1.8 | 91.5 | 2.3 | 0.3 | 7.0 | 3.0 | 27.5 | 7.5 | 12.2 | 3.9 | |
| Clobenpropit | CPD000469632 | 10.2 | 89.0 | 3.8 | 0.8 | 9.0 | 3.0 | 35.0 | 0.0 | 9.3 | 3.9 | |
| Salmeterol | CPD000466295 | 1.4 | 88.5 | 3.5 | 0.5 | 8.5 | 2.5 | 33.0 | 17.0 | 9.4 | 3.9 | |
| Azelastine | CPD000469183 | 0.5 | 82.1 | 2.9 | 1.1 | 6.3 | 2.8 | 24.1 | 5.9 | 8.3 | 3.9 | |
| Desloratadine | CPD000149358 | 1.4 | 88.4 | 2.3 | 0.2 | 6.5 | 1.0 | 24.0 | 6.0 | 10.4 | 3.7 | |
| AM-251 | CPD000466284 | 12.9 | 94.2 | 3.2 | 1.4 | 8.3 | 1.8 | 30.0 | 0.0 | 9.5 | 3.6 | |
| Rifabutin | CPD000466322 | 12.7 | 87.0 | 6.0 | 3.0 | 13.0 | 7.0 | 42.5 | 7.5 | 7.1 | 3.3 | |
| Indatraline | CPD000449273 | 0.7 | 68.1 | 1.1 | 0.1 | 3.0 | 0.0 | 9.2 | 0.8 | 8.1 | 3.1 | |
| Nelfinavir | CPD000469186 | 0.8 | 95.3 | 3.7 | 0.3 | 8.5 | 0.5 | 23.9 | 1.9 | 6.4 | 2.8 | HCV replication (21) |
| Haloperidol | CPD000449283 | 2.4 | 89.8 | 3.3 | 1.3 | 10.5 | 4.5 | 28.0 | 4.0 | 8.6 | 2.7 | EBV entry (24) |
| Benproperine | CPD000469294 | 3.4 | 98.0 | 4.0 | 2.0 | 8.5 | 2.5 | 22.5 | 2.5 | 5.6 | 2.6 | |
| M-paroxetine | CPD000469181 | 7.8 | 99.0 | 3.0 | 1.0 | 10.5 | 4.5 | 24.6 | 4.6 | 8.3 | 2.3 | |
| Carvedilol | CPD000449280 | 0.7 | 76.0 | 4.5 | 0.5 | 8.0 | 2.0 | 16.5 | 1.5 | 3.7 | 2.1 | |
| Calcipotriol | CPD000466353 | 14.1 | 93.3 | 5.5 | 0.5 | 14.0 | 2.0 | 26.6 | 6.4 | 4.8 | 1.9 | |
| Nitazoxanide | CPD000466367 | 6.3 | 69.5 | 2.3 | 0.5 | 10.0 | 0.0 | 14.7 | 4.7 | 6.3 | 1.5 | HCV replication(22) |
Displayed are NCC library compounds showing antiviral activity (>15% HCV infection) at 10 μM with no associated toxicity (>70% cell biomass). NCC compound number permits access to extensive compound information through PubChem (http://pubchem.ncbi.nlm.nih.gov). Data are shown as average and mean error of a minimum of two independent experiments performed in duplicate, except for original screening values, which represent average values of duplicate wells.